TICKERNERD
Menu
NTRANTRAHealthcare · Diagnostics & Research

NTRA Stock Forecast: Natera, Inc. Price Predictions for 2026-2027

Last close, 9 Sept 2026
$330
+1.90% on the day

The 22 Wall Street analysts covering Natera, Inc. hold a median 12-month price target of $350 — +6.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 8 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$47.6B
Ticker Nerd rank
81 / 100
Median analyst target
$350
Analysts covering
22
Revenue$752.8M+37.7% y/y
Operating income−$75.8M
Net income−$67.0M
Free cash flow−$8.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.0%
1M
+2.5%
YTD
+44.2%
1Y
+87.3%
From 52W high
−2.5%
From 52W low
+106.2%
$160
$339
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NTRA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Natera, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
81 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Quality
92
Revisions
90
Volatility
69
Growth
62
Value
61
Accruals
59
Issuance
26
Size
6

Momentum (98): The shares have been drifting up relative to others.

Issuance (26): The company has been issuing shares or taking on financing, diluting existing holders.

Size (6): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NTRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NTRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300$350$400Oct 25Jan 26Apr 26Jul 26NTRAHigh $376Median $350Low $280

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says22 analysts
19 Buy3 Hold0 Sell
Low $280Median $350High $376

The green dot is the last close — the median target sits +6.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 15 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
9 Sept 2026UBSMaintainsBuy$290 → $435
8 Sept 2026Rothschild & CoInitiatesBuy$385
13 Aug 2026CitigroupMaintainsBuy$315 → $365
12 Aug 2026GuggenheimMaintainsBuy$290 → $360
12 Aug 2026Piper SandlerMaintainsOverweight$249 → $364
12 Aug 2026Stephens & Co.MaintainsOverweight$305 → $350
7 Aug 2026BTIGMaintainsBuy$290 → $320
7 Aug 2026CitigroupMaintainsBuy$300 → $315
7 Aug 2026Evercore ISI GroupMaintainsOutperform$300 → $360
7 Aug 2026JP MorganMaintainsOverweight$315 → $360
7 Aug 2026RBC CapitalMaintainsOutperform$275 → $350
7 Aug 2026TD CowenMaintainsBuy$325 → $340
7 Aug 2026Wells FargoMaintainsEqual-Weight$220 → $284
14 July 2026Canaccord GenuityMaintainsBuy$285 → $330
14 July 2026Canaccord GenuityMaintainsBuy—
9 July 2026Morgan StanleyMaintainsOverweight$250 → $310
9 July 2026Morgan StanleyMaintainsOverweight—
6 July 2026Evercore ISI GroupMaintainsOutperform$270 → $300
6 July 2026Evercore ISI GroupMaintainsOutperform—
29 June 2026GuggenheimMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NTRA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NTRA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Sept 2026, Natera, Inc. returned +87.3% against +18.5% for the S&P 500, dividends included.

NTRA vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Oct 25Jan 26Apr 26Jul 26NTRAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NTRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
13
Analysts cutting
1
Fundamentals

Natera, Inc. (NTRA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−217.3×

Cheaper than 99% of US stocks

Price / sales
17.6×

Cheaper than 10% of US stocks

Price / book
26.0×

Cheaper than 4% of US stocks

EV / EBITDA
−208.4×

Cheaper than 97% of US stocks

Growth & margins
Revenue growth (YoY)
37.7%

Higher than 82% of US stocks

Earnings growth (YoY)
—
Gross margin
64.5%

Higher than 78% of US stocks

Operating margin
−10.3%

Higher than 24% of US stocks

Net margin
−7.1%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−12.5%

Higher than 35% of US stocks

Return on assets
−8.1%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Natera, Inc. (NTRA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Natera, Inc. has a market value of $47.6B and an enterprise value of $46.8B.

  • Revenue in the twelve months to 30 June 2026: $2.7B. The latest quarter grew 37.7% year on year.

  • Net income over the same four quarters: −$192.3M, a −7.1% net margin.

  • Free cash flow in the twelve months to 30 June 2026: $51.2M.

  • Shares outstanding: 143.6M.

  • Trailing P/E: −217.3×; forward P/E: −3209.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Natera, Inc. employs 6,135 people — $441K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 10 Sept 2026

Data provided by Twelve Data

Peers

NTRA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
NTRANatera, Inc.$47.6B
81
IQVIQVIA Holdings, Inc.$42.7B
91
AAgilent Technologies, Inc.$41.6B
87
IDXXIDEXX Laboratories, Inc.$41.5B
92
WATWaters Corp.$39.5B
52
ILMNIllumina, Inc.$31.9B
95
MTDMettler-Toledo International, Inc.$27.1B
91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Natera, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NTRA news & analysis

Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia)

The Motley Fool · 8 Sept 2026positive

The Motley Fool notes that billionaire investor Stanley Druckenmiller's largest stockholding is Natera, a company specializing in DNA diagnostics, while his positions in Amazon and Alphabet are smaller.

Why it matters — The item highlights that a well-known billionaire investor holds Natera as his top stock position, drawing attention to the company among NTRA watchers.

Why Moderna's Cancer Vaccine Matters to Investors

ETF Trends · 2 Sept 2026positive

The article discusses the healthcare industry's shift toward individualized therapies, moving away from mass-produced, one-size-fits-all treatments. This evolution aims to provide more effective treatments with lower risk of adverse side effects by aligning with a patient's unique biology.

Why it matters — Natera watchers would care because the industry's broader move toward personalized, biology-aligned treatments aligns with Natera's focus on individualized diagnostics and genomic testing.

New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma

Business Wire · 1 Sept 2026positive

Natera announced the publication of new data in Blood Neoplasia validating the prognostic and predictive value of Signatera for minimal residual disease assessment in patients with newly diagnosed and relapsed/refractory lymphoma. The announcement highlights the limitations of standard PET/CT scans, whose positive predictive value has been reported as low as 50%.

Why it matters — A NTRA watcher would care because new clinical validation of Signatera in lymphoma could broaden the test's potential applications beyond its current use.

Natera & Angiex Partner to Evaluate AGX101 Response With Signatera

Zacks Investment Research · 28 Aug 2026positive

Natera has partnered with Angiex to use its Signatera test in a Phase 1 trial of AGX101. The collaboration aims to track circulating tumor DNA (ctDNA) to gain deeper insight into treatment response.

Why it matters — This collaboration extends Signatera's application into another oncology trial setting, which could broaden its clinical evidence and relevance for NTRA watchers.

Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

Business Wire · 28 Aug 2026positive

Natera announced a national partnership with Susan G. Komen, the leading breast cancer organization, aimed at accelerating breast cancer awareness and education, including efforts to increase understanding of minimal residual disease (MRD). Natera's Signatera MRD test is supported by more than 185 peer-reviewed publications across multiple cancer types.

Why it matters — This partnership raises awareness of Natera's Signatera MRD test through a prominent national breast cancer organization, potentially expanding the company's reach and visibility in the oncology space.

FAQ

Frequently asked questions about NTRA stock

What is the NTRA stock price forecast for 2026-2027?

The 22 Wall Street analysts covering Natera, Inc. have a median 12-month price target of $350, with estimates ranging from $280 to $376. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NTRA stock a buy right now?

Of the 22 analysts covering Natera, Inc., 19 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Natera, Inc. 81 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NTRA?

As at 8 Sept 2026, Natera, Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will NTRA stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +6.0% from the last close, and Ticker Nerd's factor model ranks Natera, Inc. 81 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NTRA stock forecast for 2030?

No analyst covering Natera, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $280 to $376 over the next 12 months.

How has NTRA stock performed over the past year?

Natera, Inc. returned +87.3% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Natera, Inc. do?

Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use.

What is the latest news on NTRA?

The most recent item we track (The Motley Fool, 8 Sept 2026): "Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia)". The Motley Fool notes that billionaire investor Stanley Druckenmiller's largest stockholding is Natera, a company specializing in DNA diagnostics, while his positions in Amazon and Alphabet are smaller.

Company

About Natera, Inc.

Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use. The company focuses on oncology, women’s health, and organ health, using proprietary molecular assays and bioinformatics to help detect and monitor genetic conditions and disease-related changes from small blood samples. Its current product portfolio includes prenatal screening, carrier screening, cancer monitoring, and transplant rejection assessment tests, serving physicians, hospitals, health systems, transplant centers, and biopharma partners. Natera’s tests are used to support areas such as reproductive health, cancer residual disease monitoring, recurrence surveillance, and organ transplant management. Headquartered in Austin, Texas, Natera plays an important role in the growing precision medicine market by providing non-invasive diagnostic tools that help inform clinical decision-making across multiple medical specialties.

CEO Mr. Steven Leonard Chapman · 6,135 employees · United States · https://www.natera.com